On May 23, 2024, Radar Therapeutics Inc closed the transaction. The company received $13,400,000 in a round of funding led by a new investor, NFX Capital Management, LLC. The transaction included participation from new investors, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors.
Market Closed -
Other stock markets
|
After market 00:43:43 | |||
890.1 USD | +0.70% |
|
890.7 | +0.06% |
06-24 | Trending : Lilly Anti-Obesity Drug Tirzepatide Reduces Sleep Apnea Severity in Studies | DJ |
06-24 | Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.70% | 801B | |
+41.58% | 631B | |
-4.86% | 359B | |
+21.96% | 337B | |
+11.47% | 305B | |
+17.72% | 245B | |
+4.46% | 231B | |
+13.13% | 219B | |
+10.46% | 171B | |
-1.49% | 161B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Radar Therapeutics announced that it has received $13.4 million in funding from NFX Capital Management, LLC, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors